AR078293A1 - Composicion oftalmica acuosa inyectable y metodo para utilizarla - Google Patents

Composicion oftalmica acuosa inyectable y metodo para utilizarla

Info

Publication number
AR078293A1
AR078293A1 ARP100103414A ARP100103414A AR078293A1 AR 078293 A1 AR078293 A1 AR 078293A1 AR P100103414 A ARP100103414 A AR P100103414A AR P100103414 A ARP100103414 A AR P100103414A AR 078293 A1 AR078293 A1 AR 078293A1
Authority
AR
Argentina
Prior art keywords
mass
composition
therapeutic agent
increased viscosity
eye
Prior art date
Application number
ARP100103414A
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of AR078293A1 publication Critical patent/AR078293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion oftálmica adecuada para la inyeccion intravitrea. La composicion incluye una cantidad de agente complejante que reacciona con uno o más componentes endogenos (por ejemplo, ácido hialuronico) del ojo para formar una masa de viscosidad incrementada. Esta masa puede ayudar a crear un perfil conveniente de liberacion del agente terapéutico. Reivindicacion 1: Una composicion oftálmica inyectable, que comprende: un agente terapéutico; una cantidad de agente complejante suficiente como para formar una masa de viscosidad incrementada dentro del humor vítreo del ojo de un ser humano al inyectar la composicion en el ojo: y agua; en donde la masa de viscosidad incrementada se descompone en el humor vítreo para liberar el agente terapéutico y/o el agente terapéutico se esparce fuera de la masa de la viscosidad incrementada durante un largo período. Reivindicacion 2: Una composicion como en la reivindicacion 1 en donde el agente complejante está cargado positivamente y se selecciona del polímero de galactomanano, de un poli-amino ácido, de un compuesto de amonio cuaternario, de un polímero celulosico o una combinacion de los mismos. Reivindicacion 3: Una composicion como en la reivindicacion 1 o 2 en donde el agente terapéutico es una proteína o un péptido.
ARP100103414A 2009-09-23 2010-09-20 Composicion oftalmica acuosa inyectable y metodo para utilizarla AR078293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24491609P 2009-09-23 2009-09-23

Publications (1)

Publication Number Publication Date
AR078293A1 true AR078293A1 (es) 2011-10-26

Family

ID=43034434

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103414A AR078293A1 (es) 2009-09-23 2010-09-20 Composicion oftalmica acuosa inyectable y metodo para utilizarla

Country Status (15)

Country Link
US (3) US20110071091A1 (es)
EP (1) EP2480205B1 (es)
JP (2) JP5732058B2 (es)
KR (2) KR20170008895A (es)
CN (1) CN102695497B (es)
AR (1) AR078293A1 (es)
AU (1) AU2010298480B2 (es)
BR (1) BR112012006642A2 (es)
CA (1) CA2772795A1 (es)
ES (1) ES2568462T3 (es)
MX (1) MX2012003196A (es)
PL (1) PL2480205T3 (es)
TW (1) TWI492769B (es)
WO (1) WO2011037908A1 (es)
ZA (1) ZA201201438B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US20140178327A1 (en) 2012-12-21 2014-06-26 Coopervision International Holding Company, Lp Antimicrobial Ophthalmic Devices
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
KR102435676B1 (ko) 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160279055A1 (en) * 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
WO2015168140A1 (en) * 2014-04-28 2015-11-05 Hampton Technologies Ophthalmic compositions and methods for treating eyes
US20150366311A1 (en) 2014-06-19 2015-12-24 Coopervision International Holding Company, Lp Protection of Contact Lenses from Microbial Contamination Caused by Handling
WO2016197005A1 (en) * 2015-06-05 2016-12-08 Kato Pharmaceuticals, Inc. Extended release urea compositions
AU2016311158A1 (en) 2015-08-21 2018-04-05 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. POLYTHERAPY OF DISORDERS AND INFLAMMATORY EYE DISEASES
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
JP2021535112A (ja) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS
US20220133697A1 (en) * 2018-12-05 2022-05-05 Aldeyra Therapeutics, Inc. Injectable formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU604236B2 (en) * 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
US7947295B2 (en) * 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
BRPI0516082A (pt) 2004-09-24 2008-08-19 Hercules Inc poligalactomananos catiÈnicos de alto ds para produtos de cuidado com a pele
ES2564194T3 (es) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Formulaciones líquidas para el tratamiento de enfermedades o dolencias
CN100433805C (zh) * 2005-06-29 2008-11-12 上海广电（集团）有限公司中央研究院 一种数字电视接收机及其信号传递方法
WO2007044668A2 (en) * 2005-10-08 2007-04-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
RU2505311C2 (ru) * 2007-10-02 2014-01-27 Потентия Фармасьютикалз, Инк. Пролонгированная доставка аналогов компстатина из гелей
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
US8530189B2 (en) 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
BR112012028308B1 (pt) * 2010-05-05 2021-09-28 Alcon Inc. Formulações oftálmicas de galactomanano estabilizadas, e seu método de fabricação

Also Published As

Publication number Publication date
JP5732058B2 (ja) 2015-06-10
US20140094419A1 (en) 2014-04-03
CN102695497A (zh) 2012-09-26
PL2480205T3 (pl) 2016-09-30
WO2011037908A1 (en) 2011-03-31
KR20170008895A (ko) 2017-01-24
BR112012006642A2 (pt) 2016-05-03
ES2568462T3 (es) 2016-04-29
US20110071091A1 (en) 2011-03-24
US9446093B2 (en) 2016-09-20
TW201111003A (en) 2011-04-01
AU2010298480A1 (en) 2012-03-29
CA2772795A1 (en) 2011-03-31
EP2480205B1 (en) 2016-03-16
TWI492769B (zh) 2015-07-21
EP2480205A1 (en) 2012-08-01
JP2013505934A (ja) 2013-02-21
US20160361254A1 (en) 2016-12-15
ZA201201438B (en) 2013-05-29
JP2015129194A (ja) 2015-07-16
CN102695497B (zh) 2016-01-06
AU2010298480B2 (en) 2014-08-07
KR20120069741A (ko) 2012-06-28
MX2012003196A (es) 2012-04-30

Similar Documents

Publication Publication Date Title
AR078293A1 (es) Composicion oftalmica acuosa inyectable y metodo para utilizarla
BR112012026886A2 (pt) dispositivo de injeção automático usável para distribuição controlada de agentes terapêuticos
BR112012014710A2 (pt) botão de ignição aperfeiçoado para dispositivo de injeção automática
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
BR112018069251A2 (pt) métodos de intervenção precoce para prevenir ou melhorar a toxicidade
NZ701069A (en) Methods and devices for drug delivery to ocular tissue using microneedle
MY198078A (en) Medical device
UY28067A1 (es) Formulaciones de deposito de liberacion controlada
BRPI0410953A (pt) composições de depósito elastoméricas que podem ser implantadas, usos das mesmas e processo de produção
PE20070437A1 (es) FORMULACION ACUOSA hFSH
TW201613588A (en) Ophthalmic composition
WO2017142379A3 (ko) 피부미용장치의 핸드피스
WO2008060359A3 (en) Biodegradable ocular implants and methods for treating ocular conditions
AR112286A2 (es) Sistema polimérico de lágrimas artificiales
NZ603345A (en) Stabilized ophthalmic galactomannan formulations
MX2009004365A (es) Dispositivos oculares y metodos para la fabricacion y uso de los mismos.
JP2013505934A5 (es)
RU2011106329A (ru) Глазное устройство, обладающее способностью доставки терапевтического средства и способ получения такового
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
CO6680694A2 (es) Composición y método para la reparación y regeneración muscular
BR112015018414A2 (pt) lágrimas artificiais compreendendo hialuronato de sódio e carboximetilcelulose
AR059165A1 (es) Una ampolla utilizable como una jeringa y una unidad de jeringa que comprende la ampolla
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
AR039729A1 (es) Formulaciones de deposito de corta duracion
NZ599395A (en) Antisense formulation

Legal Events

Date Code Title Description
FB Suspension of granting procedure